Fosamax and Osteonecrosis of the Jaw: Causation and Medical Literature

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Legacy of General Health and Science Information

The legacy of general health and science information has long served as a foundation for public understanding of disease risks, often focusing on lifestyle factors and broad environmental exposures. Within this heritage, the communication of complex medical findings has evolved to address specific therapeutic contexts, including the long-term effects of pharmaceutical interventions. A notable example is the documented association between bisphosphonate medications, such as Fosamax, and the development of osteonecrosis of the jaw (ONJ), a condition extensively discussed in medical literature. This transition from general health education to a targeted pharmacological risk profile represents a natural progression in public health discourse.

Bridging to Occupational and Patient Risk Contexts

As this informational framework matures, it becomes necessary to pivot from a purely clinical perspective to consider occupational exposure concerns. While the initial focus was on patients receiving these medications for conditions like osteoporosis, the manufacturing, handling, and distribution of such compounds introduce distinct risk pathways for workers. The same active pharmaceutical ingredients that pose risks to patients may present inhalation or dermal hazards in industrial settings. This shift in focus acknowledges that the legacy of health communication must now accommodate the safety of those who produce and handle these substances, moving beyond patient-centered warnings to encompass occupational health surveillance and exposure mitigation strategies.

Fosamax Pharmacology and ONJ Association

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its pharmacological action involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a recognized adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed, non-healing bone in the maxillofacial region, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation typically involves pain, swelling, and exposed bone in the jaw, often following dental procedures. Diagnosis is based on clinical examination and imaging, with a focus on ruling out other causes such as malignancy or infection. The condition has been reported in patients taking bisphosphonates, including Fosamax and Fosamax Plus D (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanistic Pathways and Risk Factors

The mechanistic pathways linking Fosamax to ONJ are not fully elucidated but are believed to involve the drug's potent inhibition of osteoclast activity, which suppresses bone turnover. This suppression can impair the jawbone's ability to repair microdamage and respond to local stressors, such as dental infections or trauma. A multiscale characterization of jawbone has provided comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077). The jawbone's high remodeling rate and susceptibility to local inflammation may make it particularly vulnerable to the effects of bisphosphonate-induced remodeling suppression. Risk factors for ONJ in patients taking Fosamax include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Epidemiological Evidence and Causation

Regarding the timeline between exposure and documented harm, the time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). A cohort study among cancer-free female patients aged 40-89 with, or at risk for, osteoporosis in the United Kingdom Clinical Practice Research Datalink found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702). The adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information. The label includes a specific warning under section 5.4, "Osteonecrosis of the Jaw," which describes the condition, associated risk factors, and recommendations for management (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label also notes that the optimal duration of use has not been determined and that for patients at low-risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For affected patients, causation considerations involve evaluating the temporal relationship between Fosamax exposure and ONJ onset, the presence of known risk factors, and the exclusion of other causes. The label's warning and the epidemiological data support a causal association, particularly with longer duration of use. Patients who develop ONJ while on Fosamax should discontinue the drug if severe symptoms develop, and management should include dental evaluation and treatment of any local infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk of ONJ, while low, is a recognized adverse effect that requires careful consideration in the context of the benefits of osteoporosis treatment.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how does it work?

Fosamax (alendronate) is a bisphosphonate medication used to treat and prevent osteoporosis. It works by inhibiting bone resorption, thereby increasing bone mass and reducing fracture risk. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56)

What is osteonecrosis of the jaw (ONJ) and how is it linked to Fosamax?

ONJ is a condition characterized by exposed, non-healing bone in the jaw, often after dental procedures. It is a recognized adverse effect of bisphosphonates like Fosamax, believed to result from suppressed bone turnover. Risk increases with longer duration of use. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56)

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids), poor oral hygiene, and pre-existing dental disease. Duration of bisphosphonate use also increases risk. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1)

How common is ONJ in Fosamax users?

ONJ is rare. A cohort study found absolute risks of approximately 0.05% after 5 years of treatment, with risk increasing threefold after 2-3 years and eightfold after 10 years compared to past use. (https://pubmed.ncbi.nlm.nih.gov/39400702)

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.